These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 36413888)

  • 21. Molecular targets of arsenic trioxide in malignant cells.
    Miller WH
    Oncologist; 2002; 7 Suppl 1():14-9. PubMed ID: 11961205
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current status and future prospects of nanomedicine for arsenic trioxide delivery to solid tumors.
    Sönksen M; Kerl K; Bunzen H
    Med Res Rev; 2022 Jan; 42(1):374-398. PubMed ID: 34309879
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biotransformation of arsenic trioxide by AS3MT favors eradication of acute promyelocytic leukemia: revealing the hidden facts.
    Maimaitiyiming Y; Zhu HH; Yang C; Naranmandura H
    Drug Metab Rev; 2020 Aug; 52(3):425-437. PubMed ID: 32677488
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Arsenic trioxide: marked suppression of tumor metastasis potential by inhibiting the transcription factor Twist in vivo and in vitro.
    Wang GZ; Zhang W; Fang ZT; Zhang W; Yang MJ; Yang GW; Li S; Zhu L; Wang LL; Zhang WS; Liu R; Qian S; Wang JH; Qu XD
    J Cancer Res Clin Oncol; 2014 Jul; 140(7):1125-36. PubMed ID: 24756364
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Arsenic trioxide in hematological malignancies: the new discovery of an ancient drug.
    Bonati A; Rizzoli V; Lunghi P
    Curr Pharm Biotechnol; 2006 Dec; 7(6):397-405. PubMed ID: 17168655
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Self-activated arsenic manganite nanohybrids for visible and synergistic thermo/immuno-arsenotherapy.
    Zhai Y; Liu M; Yang T; Luo J; Wei C; Shen J; Song X; Ke H; Sun P; Guo M; Deng Y; Chen H
    J Control Release; 2022 Oct; 350():761-776. PubMed ID: 36063961
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The pharmacokinetics of therapeutic arsenic trioxide in acute promyelocytic leukemia patients.
    Ghiuzeli CM; Stýblo M; Saunders J; Calabro A; Budman D; Allen S; Devoe C; Dhingra R
    Leuk Lymphoma; 2022 Mar; 63(3):653-663. PubMed ID: 34689693
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel Mechanistic Insights into the Anti-cancer Mode of Arsenic Trioxide.
    Wahiduzzaman M; Ota A; Hosokawa Y
    Curr Cancer Drug Targets; 2020; 20(2):115-129. PubMed ID: 31736446
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Arsenic trioxide prevents nitric oxide production in lipopolysaccharide -stimulated RAW 264.7 by inhibiting a TRIF-dependent pathway.
    Takahashi M; Ota A; Karnan S; Hossain E; Konishi Y; Damdindorj L; Konishi H; Yokochi T; Nitta M; Hosokawa Y
    Cancer Sci; 2013 Feb; 104(2):165-70. PubMed ID: 23106696
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Subcellular Partitioning of Arsenic Trioxide Revealed by Label-Free Imaging.
    Huang S; Chen K; Leung JK; Guagliardo P; Chen W; Song W; Clode P; Xu J; Young SG; Jiang H
    Anal Chem; 2022 Oct; 94(40):13889-13896. PubMed ID: 36189785
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Arsenic trioxide.
    Litzow MR
    Expert Opin Pharmacother; 2008 Jul; 9(10):1773-85. PubMed ID: 18570609
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Meta-analysis of all-trans retinoic acid-linked arsenic trioxide treatment for acute promyelocytic leukemia.
    Chen L; Wang J; Hu X; Xu X
    Hematology; 2014 Jun; 19(4):202-7. PubMed ID: 24074286
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A candidate for lung cancer treatment: arsenic trioxide.
    Huang W; Zeng YC
    Clin Transl Oncol; 2019 Sep; 21(9):1115-1126. PubMed ID: 30756240
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multicenter randomized trial of arsenic trioxide and Realgar-Indigo naturalis formula in pediatric patients with acute promyelocytic leukemia: Interim results of the SCCLG-APL clinical study.
    Yang MH; Wan WQ; Luo JS; Zheng MC; Huang K; Yang LH; Mai HR; Li J; Chen HQ; Sun XF; Liu RY; Chen GH; Feng X; Ke ZY; Li B; Tang YL; Huang LB; Luo XQ
    Am J Hematol; 2018 Dec; 93(12):1467-1473. PubMed ID: 30160789
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Homoharringtonine potentiates the antileukemic activity of arsenic trioxide against acute myeloid leukemia cells.
    Chen P; Zhan W; Wang B; You P; Jin Q; Hou D; Wang X; You R; Zou H; Chen Y; Huang H
    Exp Cell Res; 2019 Mar; 376(2):114-123. PubMed ID: 30763586
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In the war against solid tumors arsenic trioxide needs partners.
    Subbarayan PR; Ardalan B
    J Gastrointest Cancer; 2014 Sep; 45(3):363-71. PubMed ID: 24825822
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide: review of clinical and basic studies.
    Liu P; Han ZC
    Int J Hematol; 2003 Jul; 78(1):32-9. PubMed ID: 12894848
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Determination of arsenic metabolites in patients with newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide.
    Zhang Z; Chen Y; Meng H; Sui M; Zhou Q; Shi C; Han L; Wang H; Zhou J
    Leuk Lymphoma; 2013 Sep; 54(9):2041-6. PubMed ID: 23343178
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Arsenic trioxide: mechanisms of action.
    Davison K; Mann KK; Miller WH
    Semin Hematol; 2002 Apr; 39(2 Suppl 1):3-7. PubMed ID: 12012315
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bone-targeting nanoparticle to co-deliver decitabine and arsenic trioxide for effective therapy of myelodysplastic syndrome with low systemic toxicity.
    Wu X; Hu Z; Nizzero S; Zhang G; Ramirez MR; Shi C; Zhou J; Ferrari M; Shen H
    J Control Release; 2017 Dec; 268():92-101. PubMed ID: 29042320
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.